Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
Official title:
Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)
NCT number | NCT04169529 |
Other study ID # | MDT19019 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 25, 2020 |
Est. completion date | June 27, 2023 |
Verified date | October 2023 |
Source | Medtronic Cardiac Rhythm and Heart Failure |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of the LINQ™ for COPD study is to characterize Reveal LINQ™ derived data from patients with COPD by assessing the relationship between changes in LINQ™ derived data with COPD exacerbation events.
Status | Completed |
Enrollment | 42 |
Est. completion date | June 27, 2023 |
Est. primary completion date | June 27, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years and older |
Eligibility | Inclusion Criteria: - Patient is = 45 years old - Patient (or patient's legally authorized representative) is willing and able to provide written informed consent - Patient is willing and able to comply with the protocol, including follow-up visits, electronic diary submissions and CareLink transmissions - FEV1 (post bronchodilator) = 70% of predicted - Current or former smoker with lifetime cigarette consumption of > 10 pack-years - One COPD exacerbation in the previous 12 months requiring hospitalization, urgent care or emergency department visit for respiratory illness OR Two COPD exacerbations within the previous 12 months requiring antibiotics and/or corticosteroids for respiratory symptoms. - The patient's medical records must be accessible by the enrolling site over the follow-up period Exclusion Criteria: - Less than 30 days from diagnosis of a COPD exacerbation as defined as taking antibiotics and/or corticosteroids for respiratory symptoms, hospitalization, urgent care or emergency department visit for respiratory illness. - Less than 30 days from diagnosis of a HF event as defined as any cardiovascular-related (including hypervolemia) Health Care Utilizations (HCUs) for any one of the following events: - Admission with primary diagnosis of HF - Intravenous HF therapy (e.g. IV diuretics/vasodilators) or ultrafiltration at any one of the following settings: - Admission with secondary/tertiary diagnosis of HF - Emergency Department - Ambulance - Observation Unit - Urgent Care - HF/Cardiology Clinic - Active respiratory infection being treated with antibiotics and/or corticosteroids - Class IV heart failure - Clinical diagnosis of unstable angina, bronchiectasis, or cystic fibrosis - Any concomitant condition that might endanger the patient through participation in the study or interfere with study procedures, as assessed by the investigator - Patient is pregnant (all females of child-bearing potential must have a negative pregnancy test within 1 week of enrollment) - Patient is enrolled in another study that could confound the results of this study, without documented pre-approval from a Medtronic study manager - Patient has an existing or planned implantation of Medtronic IPG, ICD, CRT-D or CRT-P device in the near future - Patient has an existing and active insertable cardiac monitor, regardless of manufacturer - Concurrent disease with life expectancy less than 1 year |
Country | Name | City | State |
---|---|---|---|
United States | Bay Area Cardiology Associates | Brandon | Florida |
United States | The Ohio State University | Columbus | Ohio |
United States | Baptist Medical Center | Jacksonville | Florida |
United States | Lancaster General Hospital | Lancaster | Pennsylvania |
United States | Clinical Site Partners Inc | Leesburg | Florida |
United States | Virtua Pulmonology Marlton | Marlton | New Jersey |
United States | Northwell Health Lenox Hill Hospital | New York | New York |
United States | Oklahoma Cardiovascular Research Group | Oklahoma City | Oklahoma |
United States | Memorial Health University Medical Center | Savannah | Georgia |
Lead Sponsor | Collaborator |
---|---|
Medtronic Cardiac Rhythm and Heart Failure |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reveal LINQ™ derived data in patients with COPD | Characterizing LINQ derived data with COPD events | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Terminated |
NCT01388920 -
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
|
Phase 2 |